Primary local hyperhidrosis
Conditions
Interventions
Transdermal application of HP-5070 (oxybutynin hydrochloride)
Sponsors
Customer Service Office
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who continued into the extension - Japanese patients with primary local hyperhidrosis who completed the prior study - Patients wishing to continue to receive HP-5070 after participating in the prior study New patients - Japanese patients aged 12 years or older - Patients with a diagnosis of primary local hyperhidrosis - Patients with involvement of palmar sites
Exclusion criteria
Exclusion criteria: Patients who continued into the extension - Patients with a resting pulse rate of less than 45 beats per minute or more than 90 beats per minute measured during the pre-observation period of the prior study - Patients with a QTcF of 450 msec or more on a 12-lead ECG measured during the pre-observation period of the prior study - Patients with abnormal waveforms on a 12-lead ECG measured during the pre-observation period of the prior study New patients - Patients with secondary hyperhidrosis - Patients with heavy sweating due to climacteric disturbance - Patients who have undergone surgery for hyperhidrosis (sympathectomy, nerve block, laser surgery, etc.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse events | — |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of responders with the defined volume of sweat | — |
Contacts
Public ContactOffice Customer Service
Hisamitsu Pharmaceutical Co., Inc.
Outcome results
None listed